Lasa Supergenerics Limited (LASA) Fair Value & Analysis
Healthcare · IN · Market cap ₹372M
Fair value as of: Jul 3, 2026
From 1 valuation models · updated today
Share price −3.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹5.67 – ₹13.92 · fair‑value band ₹4.95 – ₹9.90 · the ₹7.43 price screens above the ₹6.64 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lasa Supergenerics Limited (LASA) currently trades at ₹7.43, while our model-based Fair Value estimate is ₹6.64 — implying the stock looks roughly 10.6% overvalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at ₹253M. It earns a return on equity of -51.1%. Net debt stands at ₹90.5M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Lasa Supergenerics Limited reported revenue of ₹251M in FY2026 versus ₹1.4B in FY2022, a compound −34.6%/yr. Reported net income was −₹341M in FY2026.
Is LASA fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lasa Supergenerics Limited (LASA) undervalued?
What is the fair value of LASA?
What is the quality score of LASA?
What is the revenue of Lasa Supergenerics Limited (LASA)?
What is the net profit margin of LASA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.